Six-Year Outcomes in CLL and SLL: Insights from the SEQUOIA and ALPINE Trials
Chronic Lymphocytic Leukemia/Small-Cell Lymphoma: 6-Year Follow-Up on SEQUOIA and ALPINE LTE1
This program explores evolving strategies in the management of chronic lymphocytic leukemia (CLL), with insights from Drs. Ian Flinn and Danielle Brander. The discussion focuses on the integration of BTK inhibitors and BCL2-targeted therapy, particularly zanubrutinib and venetoclax, highlighting their efficacy, safety, and practical application. Experts emphasize individualized treatment, balancing disease characteristics, comorbidities, and patient preferences, while considering therapy duration and the role of minimal residual disease (MRD)-guided approaches.
| WATCH NOW |
Featured Video
|
